More than a decade after AstraZeneca appeared to give up hope of using zibotentan to treat prostate cancer, the endothelin receptor antagonist has received a new lease on life as a combo treatment for chronic kidney disease.

After achieving a positive outcome in a preliminary look at a phase 1/2 trial for a solid tumor candidate, Kronos Bio is restructuring and cutting staff.

In a span of three days, Phathom Pharmaceuticals has scored two green lights from the FDA for its first-in-class heartburn drug Voquezna. The first came on Monday when the regulator signed off on Phathom’s reformulation of Voquezna to treat Helicobacter pylori infection. The second came on Wednesday when the FDA blessed Voquezna for gastroesophageal reflux disease erosive esophagitis (erosive GERD) and associated heartburn.

In its attempt to win approval in the United States for its groundbreaking T-cell therapy Ebvallo, Atara Biotherapeutics is turning to the same partner it used to gain a green light in Europe—Pierre Fabre Laboratories. In this geographic expansion of Pierre Fabre’s licensing rights, the French pharma takes over manufacturing, clinical and regulatory activities for Ebvallo in the U.S., Canada and other markets outside of the European Union.

If CooperSurgical’s latest acquisition deal sparks a sense of déjà vu, it’s for good reason.